Kyle Gowen

Kyle Gowen

UNVERIFIED PROFILE

Are you Kyle Gowen?   Register this Author

Register author
Kyle Gowen

Kyle Gowen

Publications by authors named "Kyle Gowen"

Are you Kyle Gowen?   Register this Author

19Publications

1039Reads

7Profile Views

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

J Thorac Oncol 2019 02;14(2):e29-e30

City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.169DOI Listing
February 2019

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Lung Cancer 2017 12 24;114:108-110. Epub 2017 Aug 24.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.018DOI Listing
December 2017

A recurrent endometrial stromal sarcoma harbors the novel fusion .

Gynecol Oncol Rep 2017 May 8;20:51-53. Epub 2017 Mar 8.

Department of Obstetrics and Gynecology and the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2017.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348601PMC
May 2017

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

Clin Cancer Res 2016 08 1;22(15):3831-40. Epub 2016 Mar 1.

Oncology Division, Department of Internal Medicine, Rhode Island Hospital, and Alpert Medical School at Brown University, Providence, Rhode Island.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-3000DOI Listing
August 2016

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Lung Cancer 2016 07 22;97:48-50. Epub 2016 Apr 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.013DOI Listing
July 2016

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Cancer Discov 2016 06 21;6(6):601-11. Epub 2016 Apr 21.

Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. Addario Lung Cancer Medical Institute, Cambridge, Massachusetts. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893907PMC
June 2016

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015